Berenberg analyst Gaurav Goparaju initiated coverage of Twist Bioscience with a Buy rating and $27 price target, implying 29% upside potential. The analyst believes Twist’s silicon-based, tech-enabled platform addresses several headwinds facing traditional DNA synthesis while also enabling new potential applications for synthetic DNA. The firm says the company’s silicon-based DNA synthesis platform is its core advantage.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on TWST:
- Twist Bioscience enters drug discovery agreement with Ono Pharmaceutical
- Twist Bioscience price target raised to $27 from $18 at Baird
- Twist Bioscience price target raised to $26 from $20 at Barclays
- Twist Bioscience raises Q4 revenue view to $64M-$63M from $62M-$63M
- Twist Bioscience raises FY23 revenue view to $241M-$242M from $235M-$238M
